Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

Insys Therapeutics Pleads Guilty to Opioid Kickbacks, Set to Pay $225 Million

Listen to the article now

Insys Therapeutics, a pharmaceutical company based in Chandler, Arizona, agreed to plead guilty to fraud and charges of giving kickbacks to medical doctors in exchange for them prescribing Insys’ addictive opioids.

Insys has agreed to pay $225 million for using kickbacks and other illicit strategies in order to sell greater quantities of their product Subsys, a spray that’s used to lessen pain in cancer patients. Subsys contains fentanyl, which is 100 times stronger than morphine.

On May 02, five ex-Insys executives, including founder John Kapoor, were convicted on racketeering charges. The share price of the company has decreased by 93% since August.

The company will have to pay a $2 million fine, forfeit another $28 million, and pay $195 million for defrauding the U.S. Government under the False Claims Act.

U.S. Attorney Andrew Lelling said: “For years, Insys engaged in prolonged, illegal conduct that prioritized its profits over the health of the thousands of patients who relied on it. Today, the company is being held responsible.”

Insys was accused of using fake “speaker programs”, which were in reality just a means to bribe off doctors, who would, in exchange for these kickbacks, prescribe their drug Subsys to more patients, and in greater doses, even when there was no medical need for it.

The U.S. Centers for Disease Control and Prevention has warned that similar opioids – both prescription medicines as well as illicit drugs such as heroin – were involved in 47,600 deaths from overdose in 2017, a record number.


Comment Template

You May Also Like

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok